In the claims:

1. (currently amended) A compound of formula I

wherein:

 $A = CR^1 \text{ or } N,$

 $B = CR^2$ or N,

 $D = CR^3$ or N,

E = CR4 or N and

 $F = CR^5$ or N;

and the maximum number of nitrogen atoms amongst A, B, D, E, and F is two;

where m = 1-3 and n = 1-3 where m=1 and n=2;

and excluding all compounds where m = n = 2;

where each R^1 , R^2 , R^3 , R^4 and R^5 is independently selected from F, CI, Br, I, nitro, cyano, CF_3 , $-NR^6R^7$, $-NR^6C(=O)R^7$, $-NR^6C(=O)NR^7R^8$, $-NR^6C(=O)OR^7$, $-NR^6S(=O)_2R^7$, $-NR^6S(=O)_2NR^7R^8$, $-OR^6$, $-OC(=O)R^6$, $-OC(=O)R^6$, $-OC(=O)NR^6R^7$, $-OC(=O)SR^6$, $-C(=O)R^6$, $-C(=O)R^6$, $-C(=O)R^6$, $-C(=O)R^6$, $-S(=O)_2R^6$, $-S(=O)_2NR^6R^7$, and a substituent from the definition of R^6 ;

each R^6 , R^7 , and R^8 is independently selected from H, straight chain or branched (C_1 - C_8)alkyl, straight chain or branched (C_2 - C_8)alkenyl, straight chain or branched (C_2 - C_8)alkynyl, (C_3 - C_8)cycloalkyl, (C_4 - C_8)cycloalkenyl, 3-8 membered heterocycloalkyl, (C_5 - C_{11})bicycloalkyl, (C_7 - C_{11})bicycloalkenyl, 5-11 membered heterobicycloalkenyl, (C_6 - C_{11}) aryl, and 5-12 membered heteroaryl; wherein each R^6 , R^7 , and R^8 is optionally substituted with from one to six substituents, independently selected from F, Cl, Br, I, nitro, cyano, CF_3 , $-NR^9R^{10}$, $-NR^9C(=O)R^{10}$, $-NR^9C(=O)R^{10}$, $-NR^9S(=O)_2R^{10}$, $-NR^9S(=O)_2NR^{10}R^{11}$, $-OR^9$, $-OC(=O)R^9$, $-OC(=O)R^9$, $-C(=O)R^9$

or R¹ and R², or R² and R³, or R³ and R⁴, or R⁴ and R⁵, may form another 6-membered aromatic or heteroaromatic ring sharing A and B, or B and D, or D and E, or E and F, respectively, and may be optionally substituted with from one to four substituents independently selected from the group of radicals set forth in the definition of R⁶, R⁷ and R⁸ above;

each R^9 , R^{10} and R^{11} is independently selected from H, straight chain or branched (C_1 - C_8)alkyl, straight chain or branched (C_2 - C_8)alkenyl, straight chain or branched (C_2 - C_8)alkynyl, (C_3 - C_8)cycloalkyl, (C_4 - C_8)cycloalkenyl, 3-8 membered heterocycloalkyl, (C_5 - C_{11})bicycloalkyl, (C_7 - C_{11})bicycloalkenyl, 5-11 membered heterobicycloalkyl, (5-11 membered) heterobicycloalkenyl, (C_6 - C_{11}) aryl or 5-12 membered heteroaryl; wherein each R^9 , R^{10} and R^{11} is optionally substituted with from one to six substituents independently selected from F, Cl, Br, I, nitro, cyano, CF_3 , $-NR^{12}R^{13}$, $-NR^{12}C(=O)R^{13}$, $-OC(=O)R^{12}$, $-OC(=O)R^{1$

each R^{12} , R^{13} , and R^{14} is independently selected from H, straight chain or branched (C_1 - C_8)alkyl, straight chain or branched (C_2 - C_8)alkenyl, straight chain or branched (C_2 - C_8)alkynyl, (C_3 - C_8)cycloalkyl, (C_4 - C_8)cycloalkenyl, 3-8 membered heterocycloalkyl, (C_5 - C_{11})bicycloalkenyl, 5-11 membered heterobicycloalkyl, 5-11 membered heterobicycloalkenyl, (C_6 - C_{11}) aryl and (5-12 membered) heteroaryl;

and all <u>or an</u> enantiomeric, diastereomeric <u>and or</u> tautomeric <u>isomers and isomer thereof or a</u> pharmaceutically acceptable <u>salts</u> <u>salt</u> thereof.

- 2. (original) A compound according to claim 1 wherein one or two of A, B, D or E is N.
- 3. (original) A compound according to claim 1 wherein A and B are both N.
- 4. (original) A compound according to claim 1 wherein A and E are both N.
- 5. (original) A compound according to claim 1 wherein B and E are both N.
- 6. (original) A compound according to claim 1wherein one of A, B or E is N.
- 7. (original) A compound according to claim 1 wherein one of A or B is N.
- 8. (original) A compound according to claim 1 wherein each R^1 , R^2 , R^3 , R^4 and R^5 is independently selected from H, halo, $(C_1\text{-}C_6)$ alkyl, $(C_1\text{-}C_6)$ alkoxy, $(C_1\text{-}C_6)$ fluoroalkyl, cyano, $(C_1\text{-}C_6)$ alkoxycarbonyl; phenyl substituted or unsubstituted with halo, $(C_1\text{-}C_6)$ alkyl, $(C_1\text{-}C_6)$ alkoxy, $(C_1\text{-}C_6)$ fluoroalkyl; and heteroaryl; or where any one of the R^1 and R^2 , or R^2 and R^3 , or R^3 and R^4 , or R^4 and R^5 pairs located on adjacent carbon atoms join to form an unsaturated (C_4) alkylene bridge.

- 9. (cancelled) A compound according to claim 1 wherein m =1 and n =1
- 10. (cancelled) A compound according to claim 1 wherein m =1 and n =2.
- 11. (cancelled) A compound according to claim 1 wherein m =1 and n =3.
- 12. (cancelled) A compound according to claim 1 wherein m = 2 and n = 3.
- 13. (cancelled) A compound according to claim 1 wherein m = 3 and n = 3.
- 14. (original) A compound according to claim 1 selected from the group consisting of:
- 4-(5-Bromo-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- 4-(5-Phenyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- 4-Pyridin-2-yl-1,4-diaza-bicyclo[3.2.1]octane;
- 4-Pyridin-3-yl-1,4-diaza-bicyclo[3.2.1]octane:
- 4-Pyridin-4-yl-1,4-diaza-bicyclo[3.2.1]octane:
- 4-(5-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- 4-(5-Bromo-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- 4-(6-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane:
- 4-Pyrazin-2-yl-1,4-diaza-bicyclo[3.2.1]octane;
- 4-Pyrimidin-5-yl-1,4-diaza-bicyclo[3.2.1]octane;
- 4-(5-Chloro-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- 4-[5-(3-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- 4-(3-Bromo-phenyl)-1,4-diaza-bicyclo[3.2.1]octane;
- 5-(1,4-Diaza-bicyclo[3.2.1]oct-4-yl)-nicotinonitrile;
- 4-(5-Trifluoromethyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- 4-[5-(2-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- 4-[5-(4-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- 4-[5-(2-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- 4-[5-(4-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- 3-(1,4-Diaza-bicyclo[3.2.1]oct-4-yl)-quinoline;

- 4-(3-Trifluoromethyl-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- 4-(6-Methoxy-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- 4-[5-(2-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- 4-[5-(3-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- 4-(5-o-Tolyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- 5-(1,4-Diaza-bicyclo[3.2.1]oct-4-yl)-nicotinic acid ethyl ester;
- 4-(5-Chloro-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- 4-(6-Methyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- 4-[5-(3-Trifluoromethyl-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- 4-[5-(4-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- 4-(5-o-Tolyl-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- 4-[5-(3-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- 4-[5-(3-Fluoro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- 4-[5-(4-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane:
- 4-[5-(2,4-Dichloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- 4-[5-(3-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- 4-(5-p-Tolyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- 4-[5-(4-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- 4-(5-Methoxy-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- 5-(1,4-Diaza-bicyclo[3.2.1]oct-4-yl)-[3,4']bipyridinyl; and
- 4-(2-Methyl-5-trifluoromethyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane.
- 15. (original) A compound according to claim 1 selected from the group consisting of:
- (+)-4-(5-Bromo-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-4-(5-Phenyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-4-Pyridin-2-yl-1.4-diaza-bicyclo[3.2.1]octane:
- (+)-4-Pyridin-3-yl-1,4-diaza-bicyclo[3.2.1]octane;

- (+)-4-Pyridin-4-yl-1,4-diaza-bicyclo[3.2.1]octane:
- (+)-4-(5-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-4-(5-Bromo-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-4-(6-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-4-Pyrazin-2-yl-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-4-Pyrimidin-5-yl-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-4-(5-Chloro-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-4-[5-(3-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-4-(3-Bromo-phenyl)-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-5-(1,4-Diaza-bicyclo[3.2.1]oct-4-yl)-nicotinonitrile;
- (+)-4-(5-Trifluoromethyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-4-[5-(2-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-4-[5-(4-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-4-[5-(2-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane:
- (+)-4-[5-(4-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-3-(1,4-Diaza-bicyclo[3.2.1]oct-4-yl)-quinoline;
- (+)-4-(3-Trifluoromethyl-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-4-(6-Methoxy-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-4-[5-(2-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-4-[5-(3-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-4-(5-o-Tolyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-5-(1,4-Diaza-bicyclo[3.2.1]oct-4-yl)-nicotinic acid ethyl ester;
- (+)-4-(5-Chloro-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-4-(6-Methyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-4-[5-(3-Trifluoromethyl-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-4-[5-(4-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.2.1]octane;

- (+)-4-(5-o-Tolyl-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-4-[5-(3-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-4-[5-(3-Fluoro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-4-[5-(4-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-4-[5-(2,4-Dichloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-4-[5-(3-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-4-(5-p-Tolyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-4-[5-(4-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-4-(5-Methoxy-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (+)-5-(1,4-Diaza-bicyclo[3.2.1]oct-4-yl)-[3,4']bipyridinyl; and
- (+)-4-(2-Methyl-5-trifluoromethyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane.
- 16. (original) A compound according to claim 1 selected from the group consisting of:
- (-)-4-(5-Bromo-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-(5-Phenyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-Pyridin-2-yl-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-Pyridin-3-yl-1,4-diaza-bicyclo[3.2.1]octane:
- (-)-4-Pyridin-4-yl-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-(5-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-(5-Bromo-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-(6-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-Pyrazin-2-yl-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-Pyrimidin-5-yl-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-(5-Chloro-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-[5-(3-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-(3-Bromo-phenyl)-1.4-diaza-bicyclo[3.2.1]octane:
- (-)-5-(1,4-Diaza-bicyclo[3.2.1]oct-4-yl)-nicotinonitrile;

- (-)-4-(5-Trifluoromethyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-[5-(2-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-[5-(4-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-[5-(2-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-[5-(4-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-3-(1,4-Diaza-bicyclo[3.2.1]oct-4-yl)-quinoline;
- (-)-4-(3-Trifluoromethyl-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-(6-Methoxy-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-[5-(2-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-[5-(3-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-(5-o-Tolyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-5-(1,4-Diaza-bicyclo[3.2.1]oct-4-yl)-nicotinic acid ethyl ester;
- (-)-4-(5-Chloro-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-(6-Methyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane:
- (-)-4-[5-(3-Trifluoromethyl-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-[5-(4-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.2.1]octane:
- (-)-4-(5-o-Tolyl-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-[5-(3-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-[5-(3-Fluoro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-[5-(4-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-[5-(2,4-Dichloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-[5-(3-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-(5-p-Tolyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-[5-(4-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-4-(5-Methoxy-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;
- (-)-5-(1,4-Diaza-bicyclo[3.2.1]oct-4-yl)-[3,4']bipyridinyl; and

- (-)-4-(2-Methyl-5-trifluoromethyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane.
- 17. (cancelled) A compound according to claim 1 selected from the group consisting of:
- 4-(5-Bromo-pyridin-3-yl)-1,4-diaza-bicyclo[3.1.1]heptane;
- 4-(5-Phenyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.1.1]heptane;
- 4-Pyridin-2-yl-1,4-diaza-bicyclo[3.1.1]heptane;
- 4-Pyridin-3-yl-1,4-diaza-bicyclo[3.1.1]heptane;
- 4-Pyridin-4-yl-1,4-diaza-bicyclo[3.1.1]heptane;
- 4-(5-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3.1.1]heptane;
- 4-(5-Bromo-pyridin-2-yl)-1,4-diaza-bicyclo[3.1.1]heptane;
- 4-(6-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3.1.1]heptane;
- 4-Pyrazin-2-yl-1,4-diaza-bicyclo[3.1.1]heptane;
- 4-Pyrimidin-5-yl-1,4-diaza-bicyclo[3.1.1]heptane;
- 4-(5-Chloro-pyridin-3-yl)-1,4-diaza-bicyclo[3.1.1]heptane;
- 4-[5-(3-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.1.1]heptane;
- 4-(3-Bromo-phenyl)-1,4-diaza-bicyclo[3.1.1]heptane;
- 5-(1,4-Diaza-bicyclo[3.1.1]hept-4-yl)-nicotinonitrile;
- 4-(5-Trifluoromethyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.1.1]heptane;
- 4-[5-(2-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.1.1]heptane;
- 4-[5-(4-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.1.1]heptane;
- 4-[5-(2-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.1.1]heptane;
- 4-[5-(4-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.1.1]heptane;
- 3-(1,4-Diaza-bicyclo[3.1.1]hept-4-yl)-quinoline;
- 4-(3-Trifluoromethyl-pyridin-2-yl)-1,4-diaza-bicyclo[3.1.1]heptane;
- 4-(6-Methoxy-pyridin-2-yl)-1,4-diaza-bicyclo[3.1.1]heptane;
- 4-[5-(2-Methoxy-phenyl)-pyridin-3-yl]-1.4-diaza-bicyclo[3.1.1]heptane:
- 4-[5-(3-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.1.1]heptane;

- 4-(5-o-Tolyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.1.1]heptane;
- 5-(1,4-Diaza-bicyclo[3.1.1]hept-4-yl)-nicotinic acid ethyl ester;
- 4-(5-Chloro-pyridin-2-yl)-1,4-diaza-bicyclo[3.1.1]heptane;
- 4-(6-Methyl-pyridin-3-yl)-1,4-diaza- bicyclo[3.1.1]heptane;
- 4-[5-(3-Trifluoromethyl-phenyl)-pyridin-2-yl]-1,4-diaza- bicyclo[3.1.1]heptane;
- 4-[5-(4-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.1.1]heptane;
- 4-(5-o-Tolyl-pyridin-2-yl)-1,4-diaza- bicyclo[3.1.1]heptane;
- 4-[5-(3-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza- bicyclo[3.1.1]heptane;
- 4-[5-(3-Fluoro-phenyl)-pyridin-2-yl]-1,4-diaza- bicyclo[3.1.1]heptane;
- 4-[5-(4-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.1.1]heptane;
- 4-[5-(2,4-Dichloro-phenyl)-pyridin-3-yl]-1,4-diaza- bicyclo[3.1.1]heptane;
- 4-[5-(3-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.1.1]heptane;
- 4-(5-p-Tolyl-pyridin-3-yl)-1,4-diaza- bicyclo[3.1.1]heptane;
- 4-[5-(4-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza- bicyclo[3.1.1]heptane:
- 4-(5-Methoxy-pyridin-3-yl)-1,4-diaza-bicyclo[3.1.1]heptane;
- 5-(1,4-Diaza-bicyclo[3.1.1]hept-4-yl)-[3,4']bipyridinyl; and
- 4-(2-Methyl-5-trifluoromethyl-pyridin-3-yl)-1,4-diaza- bicyclo[3.1.1]heptane.
- 18. (cancelled) A compound according to claim 1 selected from the group consisting of:
- 4-(5-Bromo-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- 4-(5-Phenyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- 4-Pyridin-2-yl-1,4-diaza-bicyclo[3.3.1]nonane;
- 4-Pyridin-3-yl-1,4-diaza-bicyclo[3.3.1]nonane;
- 4-Pyridin-4-yl-1,4-diaza-bicyclo[3.3.1]nonane;
- 4-(5-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- 4-(5-Bromo-pyridin-2-yl)-1.4-diaza-bicyclo[3.3.1]nonane:
- 4-(6-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3.3.1]nonane;

- 4-Pyrazin-2-yl-1,4-diaza-bicyclo[3.3.1]nonane;
- 4-Pyrimidin-5-yl-1,4-diaza-bicyclo[3.3.1]nonane;
- 4-(5-Chloro-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- 4-[5-(3-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- 4-(3-Bromo-phenyl)-1,4-diaza-bicyclo[3.3.1]nonane;
- 5-(1,4-Diaza-bicyclo[3.3.1]non-4-yl)-nicotinonitrile;
- 4-(5-Trifluoromethyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- 4-[5-(2-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- 4-[5-(4-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- 4-[5-(2-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- 4-[5-(4-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- 3-(1,4-Diaza-bicyclo[3.3.1]non-4-yl)-quinoline;
- 4-(3-Trifluoromethyl-pyridin-2-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- 4-(6-Methoxy-pyridin-2-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- 4-[5-(2-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- 4-[5-(3-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- 4-(5-o-Tolyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- 5-(1,4-Diaza-bicyclo[3.3.1]non-4-yl)-nicotinic acid ethyl ester;
- 4-(5-Chloro-pyridin-2-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- 4-(6-Methyl-pyridin-3-yl)-1,4-diaza- bicyclo[3.3.1]nonane;
- 4-[5-(3-Trifluoromethyl-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- 4-[5-(4-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza- bicyclo[3.3.1]nonane;
- 4-(5-o-Tolyl-pyridin-2-yl)-1,4-diaza- bicyclo[3.3.1]nonane;
- 4-[5-(3-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- 4-[5-(3-Fluoro-phenyl)-pyridin-2-yl]-1,4-diaza- bicyclo[3.3.1]nonane;
- 4-[5-(4-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza- bicyclo[3.3.1]nonane;

- 4-[5-(2,4-Dichloro-phenyl)-pyridin-3-yl]-1,4-diaza- bicyclo[3.3.1]nonane;
- 4-[5-(3-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- 4-(5-p-Tolyl-pyridin-3-yl)-1,4-diaza- bicyclo[3.3.1]nonane;
- 4-[5-(4-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- 4-(5-Methoxy-pyridin-3-yl)-1,4-diaza- bicyclo[3.3.1]nonane;
- 5-(1,4-Diaza-bicyclo[3.3.1]non-4-yl)-[3,4']bipyridinyl; and
- 4-(2-Methyl-5-trifluoromethyl-pyridin-3-yl)-1,4-diaza- bicyclo[3.3.1]nonane.
- 19. (cancelled) A compound according to claim 1 selected from the group consisting of:
- (+)-4-(5-Bromo-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-4-(5-Phenyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-4-Pyridin-2-yl-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-4-Pyridin-3-yl-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-4-Pyridin-4-yl-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-4-(5-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-4-(5-Bromo-pyridin-2-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-4-(6-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-4-Pyrazin-2-yl-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-4-Pyrimidin-5-yl-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-4-(5-Chloro-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-4-[5-(3-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-4-(3-Bromo-phenyl)-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-5-(1,4-Diaza-bicyclo[3.3.1]non-4-yl)-nicotinonitrile;
- (+)-4-(5-Trifluoromethyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-4-[5-(2-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-4-[5-(4-Trifluoromethyl-phenyl)-pyridin-3-yl]-1.4-diaza-bicyclo[3.3.1]nonane:
- (+)-4-[5-(2-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.1]nonane;

- (+)-4-[5-(4-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-3-(1,4-Diaza-bicyclo[3.3.1]non-4-yl)-quinoline;
- (+)-4-(3-Trifluoromethyl-pyridin-2-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-4-(6-Methoxy-pyridin-2-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-4-[5-(2-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-4-[5-(3-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-4-(5-o-Tolyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-5-(1,4-Diaza-bicyclo[3.3.1]non-4-yl)-nicotinic acid ethyl ester;
- (+)-4-(5-Chloro-pyridin-2-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-4-(6-Methyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-4-[5-(3-Trifluoromethyl-phenyl)-pyridin-2-yl]-1,4-diaza- bicyclo[3.3.1]nonane;
- (+)-4-[5-(4-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-4-(5-o-Tolyl-pyridin-2-yl)-1,4-diaza- bicyclo[3.3.1]nonane;
- (+)-4-[5-(3-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza- bicyclo[3.3.1]nonane;
- (+)-4-[5-(3-Fluoro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-4-[5-(4-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza- bicyclo[3.3.1]nonane;
- (+)-4-[5-(2,4-Dichloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-4-[5-(3-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-4-(5-p-Tolyl-pyridin-3-yl)-1,4-diaza- bicyclo[3.3.1]nonane;
- (+)-4-[5-(4-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- (+)-4-(5-Methoxy-pyridin-3-yl)-1,4-diaza- bicyclo[3.3.1]nonane;
- (+)-5-(1,4-Diaza-bicyclo[3.3.1]non-4-yl)-[3,4']bipyridinyl; and
- (+)-4-(2-Methyl-5-trifluoromethyl-pyridin-3-yl)-1,4-diaza- bicyclo[3.3.1]nonane.
- 20. (cancelled) A compound according to claim 1 selected from the group consisting of:
- (-)-4-(5-Bromo-pyridin-3-yl)-1.4-diaza-bicyclo[3.3.1]nonane:
- (-)-4-(5-Phenyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.1]nonane;

- (-)-4-Pyridin-2-yl-1,4-diaza-bicyclo[3.3.1]nonane;
- (-)-4-Pyridin-3-yl-1,4-diaza-bicyclo[3.3.1]nonane;
- (-)-4-Pyridin-4-yl-1,4-diaza-bicyclo[3.3.1]nonane;
- (-)-4-(5-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- (-)-4-(5-Bromo-pyridin-2-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- (-)-4-(6-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- (-)-4-Pyrazin-2-yl-1,4-diaza-bicyclo[3.3.1]nonane;
- (-)-4-Pyrimidin-5-yl-1,4-diaza-bicyclo[3.3.1]nonane;
- (-)-4-(5-Chloro-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- (-)-4-[5-(3-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- (-)-4-(3-Bromo-phenyl)-1,4-diaza-bicyclo[3.3.1]nonane;
- (-)-5-(1,4-Diaza-bicyclo[3.3.1]non-4-yl)-nicotinonitrile;
- (-)-4-(5-Trifluoromethyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- (-)-4-[5-(2-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- (-)-4-[5-(4-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- (-)-4-[5-(2-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- (-)-4-[5-(4-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- (-)-3-(1,4-Diaza-bicyclo[3.3.1]non-4-yl)-quinoline;
- (-)-4-(3-Trifluoromethyl-pyridin-2-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- (-)-4-(6-Methoxy-pyridin-2-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- (-)-4-[5-(2-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- (-)-4-[5-(3-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- (-)-4-(5-o-Tolyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- (-)-5-(1,4-Diaza-bicyclo[3.3.1]non-4-yl)-nicotinic acid ethyl ester;
- (-)-4-(5-Chloro-pyridin-2-yl)-1.4-diaza-bicyclo[3.3.1]nonane:
- (-)-4-(6-Methyl-pyridin-3-yl)-1,4-diaza- bicyclo[3.3.1]nonane;

- (-)-4-[5-(3-Trifluoromethyl-phenyl)-pyridin-2-yl]-1,4-diaza- bicyclo[3.3.1]nonane;
- (-)-4-[5-(4-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- (-)-4-(5-o-Tolyl-pyridin-2-yl)-1,4-diaza- bicyclo[3.3.1]nonane;
- (-)-4-[5-(3-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza- bicyclo[3.3.1]nonane;
- (-)-4-[5-(3-Fluoro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- (-)-4-[5-(4-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza- bicyclo[3.3.1]nonane;
- (-)-4-[5-(2,4-Dichloro-phenyl)-pyridin-3-yl]-1,4-diaza- bicyclo[3.3.1]nonane;
- (-)-4-[5-(3-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- (-)-4-(5-p-Tolyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.1]nonane;
- (-)-4-[5-(4-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.1]nonane;
- (-)-4-(5-Methoxy-pyridin-3-yl)-1,4-diaza- bicyclo[3.3.1]nonane;
- (-)-5-(1,4-Diaza-bicyclo[3.3.1]non-4-yl)-[3,4']bipyridinyl; and
- (-)-4-(2-Methyl-5-trifluoromethyl-pyridin-3-yl)-1,4-diaza- bicyclo[3.3.1]nonane.
- 21. (cancelled) A compound according to claim 1 selected from the group consisting of:
- 4-(5-Bromo-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- 4-(5-Phenyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- 4-Pyridin-2-yl-1,4-diaza-bicyclo[3.3.2]decane;
- 4-Pyridin-3-yl-1,4-diaza-bicyclo[3.3.2]decane;
- 4-Pyridin-4-yl-1,4-diaza-bicyclo[3.3.2]decane;
- 4-(5-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- 4-(5-Bromo-pyridin-2-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- 4-(6-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- 4-Pyrazin-2-yl-1,4-diaza-bicyclo[3.3.2]decane;
- 4-Pyrimidin-5-yl-1,4-diaza-bicyclo[3.3.2]decane;
- 4-(5-Chloro-pyridin-3-yl)-1.4-diaza-bicyclo[3.3.2]decane:
- 4-[5-(3-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.2]decane;

- 4-(3-Bromo-phenyl)-1,4-diaza-bicyclo[3.3.2]decane;
- 5-(1,4-Diaza-bicyclo[3.3.2]dec-4-yl)-nicotinonitrile;
- 4-(5-Trifluoromethyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- 4-[5-(2-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.2]decane;
- 4-[5-(4-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.2]decane;
- 4-[5-(2-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.2]decane;
- 4-[5-(4-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.2]decane;
- 3-(1,4-Diaza-bicyclo[3.3.2]dec-4-yl)-quinoline;
- 4-(3-Trifluoromethyl-pyridin-2-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- 4-(6-Methoxy-pyridin-2-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- 4-[5-(2-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.2]decane;
- 4-[5-(3-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.2]decane;
- 4-(5-o-Tolyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- 5-(1,4-Diaza-bicyclo[3.3.2]dec-4-yl)-nicotinic acid ethyl ester:
- 4-(5-Chloro-pyridin-2-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- 4-(6-Methyl-pyridin-3-yl)-1,4-diaza- bicyclo[3,3,2]decane;
- 4-[5-(3-Trifluoromethyl-phenyl)-pyridin-2-yl]-1,4-diaza- bicyclo[3.3.2]decane;
- 4-[5-(4-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza- bicyclo[3.3.2]decane;
- 4-(5-o-Tolyl-pyridin-2-yl)-1,4-diaza- bicyclo[3.3.2]decane;
- 4-[5-(3-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza- bicyclo[3.3.2]decane;
- 4-[5-(3-Fluoro-phenyl)-pyridin-2-yl]-1,4-diaza- bicyclo[3.3.2]decane;
- 4-[5-(4-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza- bicyclo[3.3.2]decane;
- 4-[5-(2,4-Dichloro-phenyl)-pyridin-3-yl]-1,4-diaza- bicyclo[3.3.2]decane:
- 4-[5-(3-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza- bicyclo[3.3.2]decane;
- 4-(5-p-Tolyl-pyridin-3-yl)-1,4-diaza- bicyclo[3.3.2]decane;
- 4-[5-(4-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza- bicyclo[3.3.2]decane;

- 4-(5-Methoxy-pyridin-3-yl)-1,4-diaza- bicyclo[3.3.2]decane;
- 5-(1,4-Diaza-bicyclo[3.3.2]dec-4-yl)-[3,4']bipyridinyl; and
- 4-(2-Methyl-5-trifluoromethyl-pyridin-3-yl)-1,4-diaza- bicyclo[3.3.2]decane.
- 22. (cancelled) A compound according to claim 1 selected from the group consisting of:
- (+)-4-(5-Bromo-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- (+)-4-(5-Phenyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- (+)-4-Pyridin-2-yl-1,4-diaza-bicyclo[3.3.2]decane;
- (+)-4-Pyridin-3-yl-1,4-diaza-bicyclo[3.3.2]decane;
- (+)-4-Pyridin-4-yl-1,4-diaza-bicyclo[3.3.2]decane;
- (+)-4-(5-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- (+)-4-(5-Bromo-pyridin-2-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- (+)-4-(6-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- (+)-4-Pyrazin-2-yl-1,4-diaza-bicyclo[3.3.2]decane;
- (+)-4-Pyrimidin-5-yl-1,4-diaza-bicyclo[3.3.2]decane;
- (+)-4-(5-Chloro-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- (+)-4-[5-(3-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.2]decane;
- (+)-4-(3-Bromo-phenyl)-1,4-diaza-bicyclo[3.3.2]decane;
- (+)-5-(1,4-Diaza-bicyclo[3.3.2]dec-4-yl)-nicotinonitrile;
- (+)-4-(5-Trifluoromethyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- (+)-4-[5-(2-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.2]decane;
- (+)-4-[5-(4-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.2]decane;
- (+)-4-[5-(2-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.2]decane;
- (+)-4-[5-(4-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.2]decane;
- (+)-3-(1,4-Diaza-bicyclo[3.3.2]dec-4-yl)-quinoline;
- (+)-4-(3-Trifluoromethyl-pyridin-2-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- (+)-4-(6-Methoxy-pyridin-2-yl)-1,4-diaza-bicyclo[3.3.2]decane;

- (+)-4-[5-(2-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.2]decane;
- (+)-4-[5-(3-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.2]decane;
- (+)-4-(5-o-Tolyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- (+)-5-(1,4-Diaza-bicyclo[3.3.2]dec-4-yl)-nicotinic acid ethyl ester;
- (+)-4-(5-Chloro-pyridin-2-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- (+)-4-(6-Methyl-pyridin-3-yl)-1,4-diaza- bicyclo[3.3.2]decane;
- (+)-4-[5-(3-Trifluoromethyl-phenyl)-pyridin-2-yl]-1,4-diaza- bicyclo[3.3.2]decane;
- (+)-4-[5-(4-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.3.2]decane;
- (+)-4-(5-o-Tolyl-pyridin-2-yl)-1,4-diaza- bicyclo[3.3.2]decane;
- (+)-4-[5-(3-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza- bicyclo[3.3.2]decane;
- (+)-4-[5-(3-Fluoro-phenyl)-pyridin-2-yl]-1,4-diaza- bicyclo[3.3.2]decane;
- (+)-4-[5-(4-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza- bicyclo[3.3.2]decane;
- (+)-4-[5-(2,4-Dichloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.2]decane;
- (+)-4-[5-(3-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza- bicyclo[3.3.2]decane:
- (+)-4-(5-p-Tolyl-pyridin-3-yl)-1,4-diaza- bicyclo[3.3.2]decane;
- (+)-4-[5-(4-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza- bicyclo[3.3.2]decane;
- (+)-4-(5-Methoxy-pyridin-3-yl)-1,4-diaza- bicyclo[3.3.2]decane;
- (+)-5-(1,4-Diaza-bicyclo[3.3.2]dec-4-yl)-[3,4']bipyridinyl; and
- (+)-4-(2-Methyl-5-trifluoromethyl-pyridin-3-yl)-1,4-diaza- bicyclo[3.3.2]decane.
- 23. (cancelled) A compound according to claim 1 selected from the group consisting of:
- (-)-4-(5-Bromo-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- (-)-4-(5-Phenyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- (-)-4-Pyridin-2-yl-1,4-diaza-bicyclo[3.3.2]decane;
- (-)-4-Pyridin-3-yl-1,4-diaza-bicyclo[3.3.2]decane;
- (-)-4-Pyridin-4-yl-1,4-diaza-bicyclo[3,3,2]decane:
- (-)-4-(5-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3.3.2]decane;

- (-)-4-(5-Bromo-pyridin-2-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- (-)-4-(6-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- (-)-4-Pyrazin-2-yl-1,4-diaza-bicyclo[3.3.2]decane;
- (-)-4-Pyrimidin-5-yl-1,4-diaza-bicyclo[3.3.2]decane;
- (-)-4-(5-Chloro-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- (-)-4-[5-(3-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.2]decane;
- (-)-4-(3-Bromo-phenyl)-1,4-diaza-bicyclo[3.3.2]decane;
- (-)-5-(1,4-Diaza-bicyclo[3.3.2]dec-4-yl)-nicotinonitrile;
- (-)-4-(5-Trifluoromethyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- (-)-4-[5-(2-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.2]decane;
- (-)-4-[5-(4-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.2]decane;
- (-)-4-[5-(2-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.2]decane;
- (-)-4-[5-(4-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.2]decane;
- (-)-3-(1,4-Diaza-bicyclo[3.3.2]dec-4-yl)-quinoline;
- (-)-4-(3-Trifluoromethyl-pyridin-2-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- (-)-4-(6-Methoxy-pyridin-2-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- (-)-4-[5-(2-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.2]decane;
- (-)-4-[5-(3-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.2]decane;
- (-)-4-(5-o-Tolyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- (-)-5-(1,4-Diaza-bicyclo[3.3.2]dec-4-yl)-nicotinic acid ethyl ester;
- (-)-4-(5-Chloro-pyridin-2-yl)-1,4-diaza-bicyclo[3.3.2]decane;
- (-)-4-(6-Methyl-pyridin-3-yl)-1,4-diaza- bicyclo[3.3.2]decane;
- (-)-4-[5-(3-Trifluoromethyl-phenyl)-pyridin-2-yl]-1,4-diaza- bicyclo[3.3.2]decane;
- (-)-4-[5-(4-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.3.2]decane;
- (-)-4-(5-o-Tolyl-pyridin-2-yl)-1,4-diaza- bicyclo[3.3.2]decane;
- (-)-4-[5-(3-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza- bicyclo[3.3.2]decane;

- (-)-4-[5-(3-Fluoro-phenyl)-pyridin-2-yl]-1,4-diaza- bicyclo[3,3,2]decane:
- (-)-4-[5-(4-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza- bicyclo[3.3.2]decane;
- (-)-4-[5-(2,4-Dichloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3,3,2]decane;
- (-)-4-[5-(3-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.2]decane;
- (-)-4-(5-p-Tolyl-pyridin-3-yl)-1,4-diaza- bicyclo[3.3.2]decane;
- (-)-4-[5-(4-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.2]decane;
- (-)-4-(5-Methoxy-pyridin-3-yl)-1,4-diaza- bicyclo[3.3.2]decane;
- (-)-5-(1,4-Diaza-bicyclo[3.3.2]dec-4-yl)-[3,4']bipyridinyl; and
- (-)-4-(2-Methyl-5-trifluoromethyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.2]decane.
- 24. (cancelled) A compound according to claim 1 selected from the group consisting of:
- 4-(5-Bromo-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.3]undecane;
- 4-(5-Phenyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.3]undecane:
- 4-Pyridin-2-yl-1,4-diaza-bicyclo[3.3.3]undecane;
- 4-Pyridin-3-yl-1,4-diaza-bicyclo[3.3.3]undecane;
- 4-Pyridin-4-yl-1,4-diaza-bicyclo[3.3.3]undecane;
- 4-(5-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3,3,3]undecane;
- 4-(5-Bromo-pyridin-2-yl)-1,4-diaza-bicyclo[3.3.3]undecane;
- 4-(6-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3.3.3]undecane;
- 4-Pyrazin-2-yl-1,4-diaza-bicyclo[3.3.3]undecane;
- 4-Pyrimidin-5-yl-1,4-diaza-bicyclo[3.3.3]undecane;
- 4-(5-Chloro-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.3]undecane;
- 4-[5-(3-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.3]undecane;
- 4-(3-Bromo-phenyl)-1,4-diaza-bicyclo[3.3.3]undecane;
- 5-(1,4-Diaza-bicyclo[3.3.3]undec-4-yl)-nicotinonitrile;
- 4-(5-Trifluoromethyl-pyridin-3-yl)-1.4-diaza-bicyclo[3.3.3]undecane:
- 4-[5-(2-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.3]undecane;

- 4-[5-(4-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.3]undecane;
- 4-[5-(2-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.3]undecane;
- 4-[5-(4-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.3]undecane;
- 3-(1,4-Diaza-bicyclo[3.3.3]undec-4-yl)-quinoline;
- 4-(3-Trifluoromethyl-pyridin-2-yl)-1,4-diaza-bicyclo[3.3.3]undecane;
- 4-(6-Methoxy-pyridin-2-yl)-1,4-diaza-bicyclo[3.3.3]undecane;
- 4-[5-(2-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.3]undecane;
- 4-[5-(3-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.3]undecane;
- 4-(5-o-Tolyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.3.3]undecane;
- 5-(1,4-Diaza-bicyclo[3.3.3]undec-4-yl)-nicotinic acid ethyl ester;
- 4-(5-Chloro-pyridin-2-yl)-1,4-diaza-bicyclo[3.3.3]undecane;
- 4-(6-Methyl-pyridin-3-yl)-1,4-diaza- bicyclo[3.3.3]undecane;
- 4-[5-(3-Trifluoromethyl-phenyl)-pyridin-2-yl]-1,4-diaza- bicyclo[3.3.3]undecane;
- 4-[5-(4-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.3.3]undecane:
- 4-(5-o-Tolyl-pyridin-2-yl)-1,4-diaza- bicyclo[3.3.3]undecane;
- 4-[5-(3-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.3.3]undecane;
- 4-[5-(3-Fluoro-phenyl)-pyridin-2-yl]-1,4-diaza- bicyclo[3.3.3]undecane;
- 4-[5-(4-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza- bicyclo[3.3.3]undecane;
- 4-[5-(2,4-Dichloro-phenyl)-pyridin-3-yl]-1,4-diaza- bicyclo[3.3.3]undecane;
- 4-[5-(3-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.3.3]undecane;
- 4-(5-p-Tolyl-pyridin-3-yl)-1,4-diaza- bicyclo[3.3.3]undecane;
- 4-[5-(4-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza- bicyclo[3.3.3]undecane;
- 4-(5-Methoxy-pyridin-3-yl)-1,4-diaza- bicyclo[3.3.3]undecane;
- 5-(1,4-Diaza-bicyclo[3.3.3]undec-4-yl)-[3,4']bipyridinyl; and
- 4-(2-Methyl-5-trifluoromethyl-pyridin-3-yl)-1.4-diaza- bicyclo[3.3.3]undecane.

25. (cancelled) A pharmaceutical composition for treating a disorder or condition selected from inflammatory bowel disease, ulcerative colitis, pyoderma gangrenosum, Crohn's disease, irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction; drug/toxin-induced cognitive impairment arising from alcohol, barbiturates, vitamin deficiencies, recreational drugs, lead, arsenic, or mercury; disease-induced cognitive impairment arising from Alzheimer's disease, senile dementia, vascular dementia, Parkinson's disease, multiple sclerosis, AIDS, encephalitis, trauma, renal and hepatic encephalopathy, hypothyroidism, Pick's disease, Korsakoff's syndrome, frontal dementia or subcortical dementia; hypertension, bulimia, anorexia, obesity, cardiac arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supramuscular palsy; dependencies and addictions on or to nicotine, tobacco products, alcohol, benzodiazepines, barbiturates, opioids or cocaine; headache, migraine, stroke, traumatic brain injury (TBI), obsessivecompulsive disorder (OCD), psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, attention deficit hyperactivity disorder (ADHD), and Tourette's Syndrome in a mammal, comprising an amount of a compound according to claim 1 that is effective in treating such disorder or condition and a pharmaceutically acceptable carrier.

26. (cancelled) A method of treating a disorder or condition selected from inflammatory bowel disease, ulcerative colitis, pyoderma gangrenosum, Crohn's disease, irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction; drug/toxin-induced cognitive impairment arising from alcohol, barbiturates, vitamin deficiencies, recreational drugs, lead, arsenic, or mercury; disease-induced cognitive impairment arising from Alzheimer's disease, senile dementia, vascular dementia, Parkinson's disease, multiple sclerosis, AIDS, encephalitis, trauma, renal and hepatic encephalopathy, hypothyroidism, Pick's disease, Korsakoff's syndrome, frontal dementia or subcortical dementia; hypertension, bulimia, anorexia, obesity, cardiac arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supramuscular palsy; chemical dependencies and addictions on or to nicotine, tobacco products, alcohol, benzodiazepines, barbiturates, opioids or cocaine; headache, migraine, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, attention deficit hyperactivity disorder (ADHD), and Tourette's Syndrome in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound according to claim 1 that is effective in treating such disorder or condition.

27. (cancelled) A pharmaceutical composition for treating a disorder or condition selected from inflammatory bowel disease, ulcerative colitis, pyoderma gangrenosum, Crohn's disease, irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction; drug/toxin-induced cognitive impairment arising from alcohol, barbiturates, vitamin deficiencies, recreational drugs, lead, arsenic, or mercury; disease-induced cognitive impairment arising from Alzheimer's disease, senile dementia, vascular dementia, Parkinson's disease, multiple sclerosis, AIDS, encephalitis, trauma, renal and hepatic encephalopathy, hypothyroidism, Pick's disease, Korsakoff's syndrome, frontal dementia or subcortical dementia; hypertension, bulimia, anorexia, obesity, cardiac arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supramuscular palsy; chemical dependencies and addictions on or to nicotine, tobacco products, alcohol, benzodiazepines, barbiturates, opioids or cocaine; headache, migraine, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, attention deficit hyperactivity disorder (ADHD), and Tourette's Syndrome in a mammal, comprising a nicotinic receptor modulating amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

28. (cancelled) A method of treating a disorder or condition selected from inflammatory bowel disease, ulcerative colitis, pyoderma gangrenosum, Crohn's disease, irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction; drug/toxin-induced cognitive impairment arising from alcohol, barbiturates, vitamin deficiencies, recreational drugs, lead, arsenic, or mercury; disease-induced cognitive impairment arising from Alzheimer's disease, senile dementia, vascular dementia, Parkinson's disease, multiple sclerosis, AIDS, encephalitis, trauma, renal and hepatic encephalopathy, hypothyroidism, Pick's disease, Korsakoff's syndrome, frontal dementia or subcortical dementia; hypertension, bulimia, anorexia, obesity, cardiac arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supramuscular palsy; chemical dependencies and addictions on or to nicotine, tobacco products, alcohol, benzodiazepines, barbiturates, opioids or cocaine; headache, migraine, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia,

dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, attention deficit hyperactivity disorder (ADHD), and Tourette's Syndrome in a mammal, comprising administering to a mammal in need of such treatment a nicotinic receptor modulating amount of a compound according to claim 1.

- 29. (cancelled) A method of treating a disease of the central nervous system which is mediated by a nicotinic receptor modulating composition according to claim 1.
- 30. (cancelled) A method of modulating cholinergic function in a patient with a need thereof comprising treating said patient with a composition according to claim 1.
- 31. (original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
- 32. (cancelled) A method for binding neuronal nicotinic acetylcholine specific receptor sites in a patient in need thereof which comprises administering to said patient a therapeutically effective amount of a compound of claim 1.
- 33. (new) A method of suppressing nicotine binding to receptor sites comprising the step of treating said receptor site with a compound of formula I.